Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Phase II Study of Ipatasertib in Combination With Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)

NCT04467801 is registered in ClinicalTrials.gov with Jun Zhang, MD, PhD as lead sponsor.

NCT NCT04467801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04467801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Phase II Study of Ipatasertib in Combination With Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)
Lead sponsor
Jun Zhang, MD, PhD
Phase
Phase 2
Overall status
Unknown status
Start date
September 14, 2021
Completion date
August 31, 2025
Enrollment
60 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iiib, nsclc stage iv